Renal denervation: Symply trapped by complexity?

European Heart Journal

Volumn 36, Issue 4, 2015, Pages 199-202

  Mahfoud, Felix ^a   Lüscher, Thomas Felix ^b  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT; SPIRONOLACTONE;

ABLATION THERAPY; ADRENERGIC SYSTEM; AFRICAN AMERICAN; ANIMAL EXPERIMENT; ANTIARRHYTHMIC ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CAUCASIAN; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); EFFERENT NERVE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; KIDNEY DENERVATION; KIDNEY NERVE; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SENSORY NERVE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; FEMALE; INNERVATION; KIDNEY; MALE; PROCEDURES; SYMPATHECTOMY;

FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; SYMPATHECTOMY;

EID: 84924415701     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu450     Document Type: Review

References (21)

1. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934.
2. Böhm M, Linz D, Ukena C, Esler M, Mahfoud F. Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond? Circ Res 2014; 115: 400-409.
3. Krum H, Sobotka P, Schlaich M, Bohm M, Esler M. Renal denervation for resistant hypertension-The Symplicity HTN-1 study-Authors reply. Lancet 2014; 383: 1885-1886.
4. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35: 1752-1759.
5. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013; 128: 132-140.
6. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J 2013; 34: 2132-2140.
7. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, Linz D, Schmieder R, Rump LC, Kindermann I, Sobotka PA, Krum H, Scheller B, Schlaich M, Laufs U, Böhm M. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-424.
8. Bhatt DL, Kandzari DE, ONeill WW, DAgostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL, SYMPLICITY HTN-3 Investigators.Acontrolled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-1401.
9. Persu A, Sapoval M, Azizi M, Monge M, Danse E, Hammer F, Renkin J. Renal artery stenosis following renal denervation: a matter of concern. J Hypertens 2014; 32: 2101-2105.
10. Mahfoud F, Urban D, Teller D, Linz D, Stawowy P, Hassel JH, Fries P, Dreysse S, Wellnhofer E, Schneider G, Buecker A, Schneeweis C, Doltra A, Schlaich MP, Esler MD, Fleck E, Böhm M, Kelle S. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. Eur Heart J 2014; 35: 2224-2231.
11. Linz D, Ukena C, Mahfoud F, Neuberger HR, Böhm M. Atrial autonomic innervation: a target for interventional antiarrhythmic therapy? J Am Coll Cardiol 2014; 63: 215-224.
12. Persu A, Jin Y, Fadl Elmula FE, Jacobs L, Renkin J, Kjeldsen S. Renal denervation after Symplicity HTN-3: an update. Curr Hypertens Rep 2014; 16: 460.
13. Lüscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J 2014; 35: 1706-1711.
14. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro JM, Mauri L, Oparil S, ONeill WW, Patel MR, Rocha-Singh K, Sobotka P, Svetkey L, Townsend RR, Bakris G. Predictors of blood pressure response in the Symplicity HTN-3 trial. Eur Heart J 2015; 36: 219-227.
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
16. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation-An interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841.
17. Mahfoud F, Lüscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefevre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Böhm M. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013; 34: 2149-2157.
18. Mahfoud F, Edelman ER, Böhm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J AmColl Cardiol 2014; 64: 644-646.
19. Sakakura K, Ladich E, Cheng Q, Otsuka F, Yahagi K, Fowler DR, Kolodgie FD, Virmani R, Joner M. Anatomic assessment of sympathetic peri-Arterial renal nerves in man. J Am Coll Cardiol 2014; 64: 635-643.
20. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
21. Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens 2014; 8: 593-598.